Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000357 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
A Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15,100
- Enrollment target
- 20
- Study locations
NCT07000357: Recruiting Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.
NCT07000357 is a Phase 3 study of Cardiovascular Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 15,100 participants, above the 2,587-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (484% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07000357, a Phase 3 study of Cardiovascular Disease, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.
Primary Outcome
To compare the effect of treatment with AZD0780 to placebo in reducing the risk of MACE-PLUS (the composite of CV death, myocardial infarction \[MI\], ischaemic stroke, acute lower limb ischaemia, major amputation of a vascular aetiology, and urgent arterial revascularisation)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (20)
Arizona
- Research Site - Gilbert
- Research Site - Glendale
- Research Site - Mesa
- Research Site - Peoria
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Scottsdale
- Research Site - Tempe
- Research Site - Tucson
- Research Site - Tucson
- Research Site - Tucson
Alabama
- Research Site - Birmingham
- Research Site - Fairhope
- Research Site - Foley
- Research Site - Huntsville
- Research Site - Mobile
- Research Site - Saraland
- Research Site - Vestavia Hills
California
- Research Site - Beverly Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,100 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2029-10-26 |
| Phase | Phase 3 |
What NCT07000357 shows while recruiting
NCT07000357 is an interventional study that assigns participants to a tested intervention. Its 15,100 participants enrollment target places it among the larger protocols in the corpus, above the 2,587-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (484% higher).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07000357 names 20 study sites across 3 states, led by Arizona, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT07000357 about?
NCT07000357 is a clinical study titled "A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event". The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl...
What is the current status of trial NCT07000357?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15,100 participants. The study started on 2025-06-04. Estimated completion is 2029-10-26.
What conditions does trial NCT07000357 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT07000357?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT07000357?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07000357 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07000357's enrollment target sits among peer trials
15,100 7th of 137 higher than 131 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI